




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 403/12, C07K 7/10 C07K 15/00	A1	(11) International Publication Number: WO 93/20067 (43) International Publication Date: 14 October 1993 (14.10.93)
(21) International Application Number: PCT/US93/02964 (22) International Filing Date: 31 March 1993 (31.03.93) (30) Priority data: 07/864,093 6 April 1992 (06.04.92) US (71) Applicant: BIOSITE DIAGNOSTICS INCORPORATED [US/US]; 11030 Roselle Street, Suite D, San Diego, CA 92121 (US). (72) Inventors: BUECHLER, Kenneth, Francis ; 12523 Manifesto Place, San Diego, CA 92130 (US). NOAR, Joseph, Barry ; 324 Via Chica Court, Solana Beach, CA 92075 (US).	(74) Agents: CONSALVI, Mary, S. et al.; Lyon & Lyon, 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US). (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF



(57) Abstract

The present invention is directed to novel benzodiazepine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the benzodiazepine metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DESCRIPTION**BENZODIAZEPINE DERIVATIVES
AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF.**Field of the Invention

This invention is in the field of ligand receptor assays, including immunoassays, for the detection of selected metabolites of benzodiazepines in a fluid sample. More particularly, this invention relates to methods for the synthesis of novel benzodiazepine derivatives and protein and polypeptide benzodiazepine derivative conjugates and labels for use in the preparation of antibodies to benzodiazepine metabolites and for use in the immunoassay process.

Background of the Invention

The benzodiazepines are a class of drugs which possess sedative and tranquilizing properties. The benzodiazepines are used clinically to treat a variety of ailments, including depression, anxiety, insomnia and muscle spasms. The class of benzodiazepines include alprazolam, bromazepam, clonazepam, diazepam, flunitrazepam, flurazepam, halazepam, lorazepam, medazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam and triazolam. The abuse of benzodiazepines has prompted a need to monitor the concentration in urine. Benzodiazepines are metabolized to a variety of derivatives and the majority of the metabolites are excreted in the urine as glucuronides, for example, see Clin. Pharm. Ther. 19, 443 (1976), Arz. Forsch. 22, 687 (1972) and Clin. Pharm. Ther. 20, 329 (1976).

The preparation of antibodies to benzodiazepine metabolites requires the synthesis of a benzodiazepine derivative in order to covalently attach the derivative to an antigenic polypeptide or protein. In addition, the benzo-

diazepine derivative is covalently attached to various polypeptides, proteins or labels for use in screening antibodies and in the immunoassay process. The benzodiazepine derivative should mimic the structure of the benzodiazepine metabolite sought to be measured. Therefore, the selection and synthesis of the types of benzodiazepine derivatives for covalent attachment to proteins, polypeptides or labels is critical. In addition, the benzodiazepine derivatives need to be stable and soluble in an aqueous solution.

Benzodiazepine compounds and conjugates for immunization and immunoassay have been described in U.S. Pat. Nos. 4,046,636, 4,083,948, 4,243,654 and 4,869,895.

Summary of the Invention

The present invention is directed to novel benzodiazepine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies to the benzodiazepine metabolites. The resulting novel antigens may be used for the production of antibodies using standard methods. Once generated, the antibodies and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.

Definitions

In accordance with the present invention and as used herein, the following terms, are defined with the following meanings, unless explicitly stated otherwise.

"Drug" shall mean any compound or ligand which either as a result of spontaneous chemical reaction or by enzyme catalyzed or metabolic reaction, generates an intrinsic activity when administered to a biological system. The drug may be metabolized to a derivative of the drug by a biological system. Common examples of drugs and their metabolites are morphine, barbiturates, tetrahydrocannabinol, phencyclidine, amphetamines, methamphetamines, opi-

ates, benzodiazepines, cocaine, estrone-3-glucuronide, pregnanediol-glucuronide, cotinine, lysergic acid diethylamide, propoxyphene, methadone, anabolic steroids and tricyclic anti-depressants.

5 "Drug derivative" shall mean a ligand derivative, drug, drug metabolite or a drug analogue conjugated to a linking group.

"Drug metabolite" shall mean a compound upstream or downstream from a drug in a biochemical or metabolic pathway, or an intermediate.

10 "Label" shall mean a signal development element or a means capable of generating a signal, for example, a dye or an enzyme. The attachment of a drug derivative to the label can be through covalent bonds, adsorption processes, hydrophobic and/or electrostatic bonds, as in chelates and the like, or combinations of these bonds and interactions.

"Binding domain" shall refer to the molecular structure associated with that portion of a receptor that binds ligand. More particularly, the binding domain may refer to a polypeptide, natural or synthetic, or nucleic acid encoding such a polypeptide, whose amino acid sequence represents a specific region of a protein, said domain, either alone or in combination with other domains, exhibiting binding characteristics which are the same or similar to those of a desired ligand/receptor binding pair. Neither the specific sequences nor the specific boundaries of such domains are critical, so long as binding activity is exhibited. Likewise, used in this context, binding characteristics necessarily includes a range of affinities, avidities and specificities, and combinations thereof, so long as binding activity is exhibited.

"Linking group" shall mean the composition between the protein, polypeptide or label and a drug or drug derivative. As one skilled in the art will recognize, to accomplish the requisite chemical structure, each of the reactants must contain the necessary reactive groups. Representative combinations of such groups are amino with

carboxyl to form amide linkages, or carboxy with hydroxy to form ester linkages or amino with alkyl halides to form alkylamino linkages, or thiols with thiols to form disulfides, or thiols with maleimides or alkylhalides to form thioethers. Obviously, hydroxyl, carboxyl, amino and other functionalities, where not present may be introduced by known methods. Likewise, as those skilled in the art will recognize, a wide variety of linking groups may be employed. The structure of the linkage should be a stable covalent linkage formed to attach the drug or drug derivative to the protein, polypeptide or label. In some cases the linking group may be designed to be either hydrophilic or hydrophobic in order to enhance the desired binding characteristics of the ligand and the receptor. The covalent linkages should be stable relative to the solution conditions under which the ligand and linking group are subjected. Generally preferred linking groups will be from 1-20 carbons and 0-10 heteroatoms (NH, O, S) and may be branched or straight chain. Without limiting the foregoing, it should be obvious to one skilled in the art that only combinations of atoms which are chemically compatible comprise the linking group. For example, amide, ester, thioether, thioester, keto, hydroxyl, carboxyl, ether groups in combinations with carbon-carbon bonds are acceptable examples of chemically compatible linking groups. Other chemically compatible compounds which may comprise the linking group are set forth in this Definitions section and hereby are incorporated by reference.

"Hydrocarbyl" shall refer to an organic radical comprised of carbon chains to which hydrogen and other elements are attached. The term includes alkyl, alkenyl, alkynyl and aryl groups, groups which have a mixture of saturated and unsaturated bonds, carbocyclic rings and includes combinations of such groups. It may refer to straight-chain, branched-chain cyclic structures or combinations thereof.

"Aryl" shall refer to aromatic groups which have at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.

5 "Carbocyclic aryl groups" shall refer to groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and optionally substituted naphthyl groups.

10 "Monocyclic carbocyclic aryl" shall refer to optionally substituted phenyl, being preferably phenyl or phenyl substituted by one to three substituents, such being advantageously lower alkyl, hydroxy, lower alkoxy, lower alkanoyloxy, halogen, cyano, trihalomethyl, lower acyl-
15 amino, lower amino or lower alkoxycarbonyl.

"Optionally substituted naphthyl" shall refer to 1- or 2-naphthyl or 1- or 2-naphthyl preferably substituted by lower alkyl, lower alkoxy or halogen.

"Heterocyclic aryl groups" shall refer to groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl, and the
25 like, all optionally substituted.

"Optionally substituted furanyl" shall refer to 2- or 3-furanyl or 2- or 3-furanyl preferably substituted by lower alkyl or halogen.

30 "Optionally substituted pyridyl" shall refer to 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl preferably substituted by lower alkyl or halogen.

"Optionally substituted thienyl" shall refer to 2- or 3-thienyl, or 2- or 3-thienyl preferably substituted by lower alkyl or halogen.

35 "Biaryl" shall refer to phenyl substituted by carbocyclic aryl or heterocyclic aryl as defined herein, ortho, meta or para to the point of attachment of the phenyl

ring, advantageously para; biaryl is also represented as the $-C_6H_4-Ar$ substituent where Ar is aryl.

"Aralkyl" shall refer to an alkyl group substituted with an aryl group. Suitable aralkyl groups include
5 benzyl, picolyl, and the like, and may be optionally substituted.

"Lower" referred to herein in connection with organic radicals or compounds respectively defines such with up to and including 7, preferably up to and including 4 and
10 advantageously one or two carbon atoms. Such groups may be straight chain or branched.

The terms (a) "alkyl amino", (b) "arylamino", and (c) "aralkylamino", respectively, shall refer to the groups $-NRR'$ wherein respectively, (a) R is alkyl and R'
15 is hydrogen or alkyl; (b) R is aryl and R' is hydrogen or aryl, and (c) R is aralkyl and R' is hydrogen or aralkyl.

The term "acyl" shall refer to hydrocarbyl-CO- or HCO-.

The terms "acylamino" refers to $RCONCR$ - and $(RCO_2N$ -
20 respectively, wherein each R is independently hydrogen or hydrocarbyl.

The term "hydrocarbyloxycarbonyloxy" shall refer to the group $ROC(O)O$ - wherein R is hydrocarbyl.

The term "lower carboalkoxymethyl" or "lower hydro-
25 carbyloxycarbonylmethyl" refers to hydrocarbyl- $OC(O)CH_2$ - with the hydrocarbyl group containing ten or less carbon atoms.

The term "carbonyl" refers to $-C(O)-$.

The term "carboxamide" or "carboxamido" refers to
30 $-CONR_2$ wherein each R is independently hydrogen or hydrocarbyl.

The term "lower hydrocarbyl" refers to any hydrocarbyl group of ten or less carbon atoms.

The term "alkyl" refers to saturated aliphatic groups
35 including straight-chain, branched chain and cyclic groups.

The term "alkenyl" refers to unsaturated hydrocarbyl groups which contain at least one carbon-carbon double bond and includes straight-chain, branched-chain and cyclic groups.

5 The term "alkynyl" refers to unsaturated hydrocarbyl groups which contain at least one carbon-carbon triple bond and includes straight-chain, branched-chain and cyclic groups.

The term "hydrocarbyloxycarbonylamino" refers to a
10 urethane, hydrocarbyl-O-CONR- wherein R is H or hydrocarbyl and wherein each hydrocarbyl is independently selected.

The term "di(hydrocarbyloxycarbonyl)amino" refers to
15 (hydrocarbyl-O-CO)₂N- wherein each hydrocarbyl is independently selected.

The term "hydrocarbylamino" refers to -NRR' wherein R is hydrocarbyl and R' is independently selected hydrocarbyl or hydrogen.

The term "mercapto" refers to SH or a tautomeric
20 form.

The term "methene" refers to $\begin{array}{c} | \\ \text{H}-\text{C}- \\ | \end{array}$.

The term "methylene" refers to -CH₂-.

25 The term "alkylene" refers to a divalent straight chain or branched chain saturated aliphatic radical.

The term "oxy" refers to -O- (oxygen).

The term "thio" refers to -S- (sulfur).

"Disulfide" refers to -S-S-.

30 "Thioester" refers to -S-C=O-.

"Thioether" refers to C-S-C.

"Ester" refers to $\begin{array}{c} \text{O} \\ || \\ \text{RCOR} \end{array}$

"Analyte" shall mean substance of natural or synthetic
35 origin sought to be detected and/or measured, said substance having a specific binding partner capable of a specific interaction with said analyte.

"Ligand" shall mean a binding partner to a ligand receptor. A substance which, if detected may be used to infer the presence of an analyte in a sample, including, without limitation, haptens, hormones, antigens, antibodies, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), metabolites of the aforementioned materials and other substances of either natural or synthetic origin which may be of diagnostic interest and have a specific binding partner therefor, i.e., the ligand receptor of a ligand-receptor assay.

"Receptor" shall mean a receptor capable of binding ligand, typically an antibody, or a fragment thereof, but which may be another ligand, depending on assay design.

"Ligand-Receptor Assay" shall mean an assay for an analyte which may be detected by the formation of a complex between a ligand and a ligand receptor which is capable of a specific interaction with that ligand. Ligand-Receptor assays may be competitive or non-competitive, homogeneous or heterogeneous.

"Immunogen" shall mean a chemical or biochemical structure, determinant, antigen or portion thereof, which elicits an immune response, including, for example, polylysine, bovine serum albumin and keyhole limpid hemocyanin (KLH).

"Antigenic" shall mean a chemical or biochemical structure, determinant, antigen or portion thereof which is capable of inducing the formation of an antibody.

Description of the Drawing


Figure 1 depicts the structures of the compounds of Examples 1-7.

Detailed Description of the Preferred Embodiments

Novel compounds are described which are used in the generation of antibodies and in the immunoassay process generally. The compounds are derivatives of benzodiazepine metabolites. The derivatization of the benzodiazepine

pine analogue for covalent attachment to proteins, polypeptides and labels occurs on either the amide nitrogen or the 3' hydroxyl position. The synthesis of the linking group between the protein, polypeptide or label and the benzodiazepine derivative is designed to achieve the desired binding of the drug derivative and the receptor. For example, the derivative may be displaced from the surface of the protein, polypeptide or label to allow the derivative to present itself to the binding domain of receptors.


In general, the compounds of this invention have the following formula:



where R is -F, -Cl


where R' is -H, -Cl, -NO₂

where R'' is a linking group comprising one of the following;



where A is a linking group of from 1 to 20 carbons and from 0 to 10 heteroatoms (NH, O, S), either branched or straight chain.

In addition, the general form of the immunogenic
 5 protein or polypeptide molecule or the protein or polypeptide molecule or label derivatized via an amide, disulfide, thioether, or ester bond to the molecule or label to a compound of the formula is of the following:



where P is an antigenic protein or polypeptide or a
 10 protein, polypeptide or label;


where x is at least one and not greater than 100;

11

where R is -F, -Cl


where R' is -H, -Cl, -NO₂

where R" is a linking group of the following:




where A is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) either branched or straight chain;

where B is a linking group ultimately attached to a protein, polypeptide or label selected from the group comprising:



10 where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

In general, the compounds of this invention also have the following formula:




where R is -F, -Cl

where R' is -H, -Cl


where R'' is -H, -CH₃

where R'' is a linking group comprising:



5 where A is a linking group of from 1 to 20 carbons
and from 0 to 10 heteroatoms (NH, O, S), either branched
or straight chain.

Also, in addition, the general form of the immunogenic protein or polypeptide molecule or the protein or polypeptide molecule or label derivatized via an amide, disulfide, thioether, or ester bond to the molecule or label to a compound of the formula is of the following:



where P is an antigenic protein or polypeptide or a protein, polypeptide or label;


where x is at least one and not greater than 100;

where R is -F, -Cl

5 where R' is -H, -Cl


where R'' is -H, -CH₃

where R''' is a linking group of the following:




where A is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) either branched or
10 straight chain;

where B is a linking group ultimately attached to a protein, polypeptide or label selected from the group comprising:



where Z is a linking group of from 1 to 20 carbons
5 and 0 to 10 heteroatoms (NH, O, S) and may be branched or
straight chain.


The preferred compounds (best mode) of this invention have the following formula:



where R is -F, -Cl


10 where R' is -H, -Cl, -NO₂

where R" is a linking group comprising one of the following;



where A is a linking group of from 1 to 20 carbons and from 0 to 10 heteroatoms (NH, O, S), either branched or straight chain.

In addition, the form of the preferred (best mode) immunogenic protein or polypeptide molecule or the protein or polypeptide molecule or label derivatized via an amide or ester bond to the molecule or label to a compound of the formula is of the following:



where P is an antigenic protein or polypeptide or a
10 protein, polypeptide or label;

where x is at least one and not greater than 100;


where R is -F, -Cl

where R' is -H, -Cl, -NO₂,

16

where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

The preferred (best mode) compounds of this invention
5 also have the following formula:




where R is -F, -Cl


where R' is -Cl

where R'' is -H, -CH₃

where R''' is a linking group comprising one of the
10 following;



In addition, the form of the preferred (best mode) immunogenic protein or polypeptide molecule or the protein or polypeptide molecule or label derivatized via an amide or ester bond to the molecule or label to a compound of
15 the formula is of the following:



where P is an antigenic protein or polypeptide or a protein, polypeptide or label;

where x is at least one and not greater than 100;

where R is -F, -Cl

5 where R' is -Cl

where R'' is -H, -CH₃

where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

10 Of particular interest are the water soluble benzodiazepine derivatives described herein. The hydrophobic nature of the benzodiazepine molecule causes it to adsorb to plastic and glass surfaces and to proteins. Thus, the benzodiazepine derivatives of the present invention are
 15 synthesized such that a carboxylic acid group is introduced into the molecule to improve the water solubility of the derivative. This is particularly important because when immunogens and protein conjugates are prepared a number of benzodiazepine derivatives, roughly 1-100, are
 20 covalently attached to the protein, polypeptide or label. The high degree of substitution can cause the precipitation of the protein or polypeptide conjugate or label if additional water solubilizing groups, for example, carboxylic acids and sulfonic acids, are not incorporated into

the benzodiazepine derivative. In addition, in the absence of water solubilizing groups on the benzodiazepine molecule the benzodiazepine derivative which is covalently attached to the protein or polypeptide can adsorb to the protein surface or can interact with each other at the protein surface and can result in fewer benzodiazepine derivatives available to bind the receptor. Thus, when the covalently attached benzodiazepine derivatives interact with each other or are adsorbed to the protein or polypeptide surface the binding affinity of the receptor for the conjugate is decreased. In general, for immunoassays, the highest possible binding affinity is preferred because this allows for a sensitive and rapid immunoassay (for example, see U.S. Pat. Nos. 5,028,535 and 5,089,391). The novel benzodiazepine derivatives described herein provide improved water solubility.

The benzodiazepines used for the synthesis of the derivatives described by the Examples herein are the N-desalkyl flurazepam and lorazepam. These derivatives were used because of the available amide nitrogen and the 3' hydroxyl for use in synthesizing the chemical linking group. One skilled in the art can recognize that other benzodiazepines with an amide nitrogen capable of performing a nucleophilic attack, such as clonazepam, oxazepam, lorazepam and bromazepam can also result in N-alkylated derivatives as taught herein. Also, benzodiazepines possessing a 3' hydroxyl, for example, oxazepam and temazepam can be derivatized at the 3' hydroxyl as taught herein.

The benzodiazepine derivatives are also synthesized as thiols or thiol esters so that their covalent attachment to proteins, polypeptides or labels can easily be performed under mild conditions, for example, pH 7 in a protein solution. The linking arm between the drug derivative and the thiol or thiol ester can be of various lengths. For example, the carboxylic acid benzodiazepine derivatives as described herein can be reacted with, for

example, homocysteine thiolactone. Also, the carboxylic acid benzodiazepine derivative can first be reacted with varying chain lengths of an aminoalkyl carboxylic acid ester, for example, 4-aminobutyric acid methyl ester, the ester can then be hydrolyzed in mild base and the resulting carboxylic acid benzodiazepine derivative can further be reacted with an amino alkylthiol ester, such as, homocysteine thiolactone. The thiol esters are hydrolyzed in dilute base, for example, 0.01 M-0.1 M potassium hydroxide, to generate the thiol group which is reacted with the thiol reactive group, such as a maleimide, an alkyl halide or a thiol. The thiol reactive group is generally on the protein, polypeptide or label but can also be incorporated onto the protein, polypeptide or label after the thiol drug reacts with the thiol reactive compound.

The protein, polypeptide or label is reacted with a reagent which incorporates a maleimide or alkylhalide into the molecule. These reagents and methods for their use are available from Pierce, Rockford, IL, for example, for incorporation of maleimide groups onto proteins, polypeptides or labels one can use succinimidyl 4-(N-maleimido-methyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB) or m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). For introduction of an alkyl halide into a protein, polypeptide or label one can use N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB) also from Pierce. The thiol reactive group, such as maleimide, an alkyl halide or a thiol can be incorporated into the protein, polypeptide or label prior to reaction with the drug thiol, but the drug thiol can also be reacted with the thiol reactive compound prior to reaction with the protein, polypeptide or label. Also, bis-maleimide compounds of varying length can be reacted with thiol containing proteins, polypeptides or labels for covalent coupling of the benzodiazepine thiol derivatives. Conversely, the bis-maleimide compound can be reacted with the thiol derivative and subsequently to the thiol con-

aining protein, polypeptide or label. Common bis-maleimides are bis-maleimido-hexane from Pierce, N,N'-bis (3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine from Sigma Chemical Co., St. Louis, MO, and 1,1'-(methylenedi-
5 4,1-phenylene)-bismaleimide from Aldrich Chem. Co., Milwaukee, WI. The thiol benzodiazepine derivatives can also form disulfides with thiol containing polypeptide, protein or label molecules as a means to incorporate the derivative into the molecule.

10 The use of drug derivatives, immunogens and protein and polypeptide conjugates for generating antibodies and for use in the immunoassay process is described, for example, in U.S. Patents 4,046,636, 4,243,654, 5,028,535 and 5,089,391.

15 Experimental Examples

Example 1

Synthesis of N-Carboxymethylflurazepam

N-Desalkylflurazepam (1.0 g, 3.5×10^{-3} mol, Alltech Assoc., Deerfield, IL) was dissolved in anhydrous dimethyl-
20 formamide (35 ml). Finely powdered anhydrous potassium carbonate (0.54 g, 3.9×10^{-3} mol) was added to the solution followed by ethyl bromoacetate (0.65 g, 3.9×10^{-3} mol). The flask was purged with argon and stirred at room temperature for 24 h. The solvent was removed in vacuo to
25 give a yellow oily residue. Ethanol (45 ml) was added to the residue followed by deionized water (35 ml). Potassium hydroxide solution (1 N, 9 ml) was added and stirred at room temperature for 1 h. Ethanol was removed in vacuo. The aqueous solution was then acidified to
30 pH 3.0 with hydrochloric acid (6 N). Diethyl ether (50 ml) was added to the acidified solution. The organic layer was extracted with deionized water (2 x 40 ml) and dried over anhydrous magnesium sulfate. The drying agent was removed by filtration and the solvent was removed
35 in vacuo to give 0.9 g yellow precipitate as the product.

Example 2Synthesis of N-[2-(2-Amino-4-Thiolbutanoic Acid Thiolactone)-Acetamide]-Flurazepam

N-Carboxymethylflurazepam (0.9 g, 2.6×10^{-3} mol) was
5 dissolved in anhydrous dimethylformamide (30 ml).
dl-Homocysteine thiolactone hydrochloride (0.44 g, 2.9×10^{-3} mol) was added to the solution followed by anhydrous
pyridine (0.48 g, 6.1×10^{-3} mol), and 1-(3-dimethylamino-
propyl)-3-ethylcarbodiimide hydrochloride (0.59 g, $3.1 \times$
10 10^{-3} mol). The flask was then purged with argon and
stirred at room temperature for 2 h. The solvent was
removed in vacuo, and ethyl alcohol (20 ml) was added to
azeotrope any residual dimethylformamide. The residue was
partitioned between 0.5 M potassium phosphate pH 7.0
15 (40 ml) and ethyl acetate (40 ml). The organic layer was
washed with deionized water (40 ml x 1) and dried over
anhydrous magnesium sulfate. The drying agent was removed
by filtration, and the solvent removed in vacuo. Diethyl
ether (20 ml) was added to the residue, and the solution
20 was then filtered to give 0.8 g of pink precipitate as the
final product.

Example 3Synthesis of N-(Cysteine)Acetamide-Flurazepam

N-[2-(2-Amino-4-thiolbutanoic acid thiolactone)aceta-
25 mide]-flurazepam (0.01 g, 2.2×10^{-5} mol) was dissolved in
0.67 ml dimethylformamide/water (70/30, v/v). Potassium
hydroxide (0.45 ml, 0.25 N) was added and the solution sat
at room temperature for 30 sec. Potassium phosphate buf-
fer (0.11 ml, 0.5 M, pH 7), was immediately added and the
30 solution was adjusted to pH 7-7.5 with hydrochloric acid
(1 N). The title compound in solution was used as is to
react with thiol reactive groups, such as maleimides,
alkyl halides or thiols, which are either free in solution
or are coupled to proteins, polypeptides or labels.

Example 4Synthesis Lormetazepam

To a stirring solution of lorazepam (3.21 g, 1.0×10^{-2} mol) in anhydrous dimethylformamide (100 ml) was added
5 anhydrous powdered potassium carbonate (1.52 g, 1.1×10^{-2} mol) followed by iodomethane (0.69 ml, 1.1×10^{-2} mol). The mixture was stirred at room temperature for 20 hours. The solvent was evaporated under vacuum, the residue was treated with water (100 ml) and was stirred at room temper-
10 ature for 2 hours. The resulting fine light yellow solid was collected by filtration and was dried under vacuum to afford 3.3 g (98%) of lormetazepam as a pale yellow solid: m.p. 201-203°C.

Example 515 Synthesis of O-Carboxymethylormetazepam

Lormetazepam (3.3 g, 9.8×10^{-3} mol) was treated with thionyl chloride (40 ml, 5.5×10^{-1} mol) and the resulting solution was refluxed with stirring for 1 hour. The excess thionyl chloride was removed by addition of toluene
20 (120 ml) and distillation until the stillhead temperature reached 110°C. The solution was allowed to cool and the residual solvent was treated with methyl glycolate (8 ml, 1.0×10^{-1} mol) and the mixture was stirred at 90°C for 30 minutes when a red, homogenous solution was obtained.
25 After cooling, the excess methyl glycolate was evaporated under vacuum and the residue was treated with methyl alcohol (50 ml). The resulting solution was then treated with 1 N potassium hydroxide solution (50 ml) and after stirring for one minute the solution was evaporated to low
30 volume under vacuum. The residual solution was treated with water (60 ml), washed with diethyl ether (2 x 60 ml) and acidified to pH 2-3 by dropwise addition of 6 N hydrochloric acid (8 ml). The mixture was treated with diethyl ether (50 ml) and stirred at room temperature for 1 hour.
35 The resulting precipitate was collected by filtration, washed with water (30 ml), diethyl ether (30 ml) and was

dried under vacuum to afford 1.3 g (34%) of O-Carboxymethylormetazepam as an off-white solid.

Example 6

Synthesis of 3-O-[2-(2-Amino-4-Thiolbutanoic Acid
5 Thiolactone)-Acetamide]-Lormetazepam

To a stirring solution of O-carboxymethylormetazepam (1.3 g, 3.3×10^{-3} mol) and dl-homocysteine thiolactone hydrochloride (0.6 g, 3.9×10^{-3} mol) in anhydrous dimethylformamide (25 ml) was added anhydrous pyridine (0.66 ml, 10 8.2×10^{-3} mol) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.82 g, 4.3×10^{-3} mol). The mixture was stirred under argon at room temperature for 6 hours. The solvent was evaporated under vacuum and the residue evaporated twice from ethyl alcohol (20 ml). 15 The residue was treated with 0.5 M potassium phosphate/0.1 M potassium borate buffer at pH 7 (20 ml) and extracted with ethyl acetate (2 x 40 ml). The combined organic layers were washed with water (20 ml), dried over anhydrous magnesium sulfate and filtered. The filtrate 20 was evaporated under vacuum and the residue treated with diethyl ether (15 ml) to yield a solid which was collected by filtration to afford 1.55 g (95%) of 3-O-[2-(2-amino-4-thiolbutanoic acid thiolactone)-acetamide]-lormetazepam as a beige solid.


25 Example 7

Synthesis of 3-O-[(Cysteine)Acetamide]-Lormetazepam

3-O-[2-(2-Amino-4-thiolbutanoic acid thiolactone)-acetamide]-lormetazepam (0.01 g, 2.0×10^{-5} mol) was dissolved in 0.41 ml dimethylformamide then 0.51 ml water was 30 added. Potassium hydroxide (0.1 ml, 1 N) was added and the solution sat at room temperature for 1 min. Potassium phosphate buffer (0.2 ml, 0.5 M, pH 7), was immediately added and the solution was adjusted to pH 7-7.5 with hydrochloric acid (1 N). The title compound in solution 35 was used as is to react with thiol reactive groups, such

as maleimides, alkyl halides or thiols, which are either free in solution or are coupled to proteins, polypeptides or labels.

2. An immunogenic protein or polypeptide molecule or a protein or polypeptide molecule or a label derivatized to a compound of the formula:




where P is an antigenic protein or polypeptide or a
5 protein, polypeptide or label;

where x is at least one and not greater than 100;

where R is -F, -Cl


where R' is -H, -Cl, -NO₂

where R'' is a linking group of the following:



where A is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) either branched or straight chain;


where B is a linking group ultimately attached to a protein, polypeptide or label selected from the group consisting of;



where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

10 3. Receptor prepared in response to an antigen comprising the compounds of claim 2.

4. Compounds of the formula:




where R is -F, -Cl

where R' is -H, -Cl


where R'' is -H, -CH₃

where R''' is a linking group consisting of one of the following:



5 where A is a linking group of from 1 to 20 carbons and from 0 to 10 heteroatoms (NH, O, S), either branched or straight chain.

5. An immunogenic protein or polypeptide molecule
 or a protein or polypeptide molecule or a label deriva-
 10 tized to a compound of the formula:



where P is an antigenic protein or polypeptide or a protein, polypeptide or label;


where x is at least one and not greater than 100;

where R is -F, -Cl

5 where R' is -H, -Cl


where R" is -H, -CH₃

where R'' is a linking group of the following:



where A is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) either branched or straight chain;


where B is a linking group ultimately attached to a protein, polypeptide or label selected from the group consisting of:



where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

6. Receptor prepared in response to an antigen comprising the compounds of claim 5.


7. Compounds of the formula:



where R is -F, -Cl

where R' is -H, -Cl, -NO₂


where R'' is a linking group consisting of one of the following:



5 where A is a linking group of from 1 to 20 carbons and from 0 to 10 heteroatoms (NH, O, S), either branched or straight chain.

8. An immunogenic protein or polypeptide molecule or a protein or polypeptide molecule or a label derivatized to a compound of the formula:

10



where P is an antigenic protein or polypeptide or a protein, polypeptide or label;

where x is at least one and not greater than 100;


where R is -F, -Cl

5 where R' is -H, -Cl, -NO₂,

where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.

9. Receptor prepared in response to an antigen
10 comprising the compounds of claim 8.

10. Compounds of the formula:




where R is -F, -Cl


where R' is -Cl

where R" is -H, -CH₃

where R''' is a linking group consisting of one of the
5 following:



11. An immunogenic protein or polypeptide molecule or a protein or polypeptide molecule or a label derivatized to a compound of the formula:



where P is an antigenic protein or polypeptide or a protein, polypeptide or label;

where x is at least one and not greater than 100;


where R is -F, -Cl

5 where R' is -Cl


where R'' is -H, -CH₃

where Z is a linking group of from 1 to 20 carbons and 0 to 10 heteroatoms (NH, O, S) and may be branched or straight chain.


10 12. Receptor prepared in response to an antigen comprising the compounds of claim 11.




EXAMPLE 1




EXAMPLE 5




EXAMPLE 2



EXAMPLE 6



EXAMPLE 3



EXAMPLE 7

FIG. 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/02964

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07D 403/12, C07K 7/10, 15/00

US CL : 540/507, 508, 512, 513; 530/324, 350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 540/507, 508, 512, 513; 530/324, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

Structure Search

Chemical Structure of claim 1

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 3,757,008 (Hellerbach) 04 Sept. 1973 <i>See entire document</i>	1-12

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 AUGUST 1993

Date of mailing of the international search report

AUG 17 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOHN M. BORD

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/02964

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(Form PCT/ISA/206 Previously Mailed.)
Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This International Searching Authority has found 3 inventions claimed in the International Application covered by the claims indicated below:

- I. Claims 1, 4, 7 and 10, drawn to 1,4-benzodiazepines, classified in Class 540, subclass 507+.
- II. Claims 2, 5, 8 and 11, drawn to peptides in Class 530, subclass 324.
- III. Claims 3, 6, 9 and 12, drawn to antigens in Class 530, subclass 350.

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The compounds of Group I are intermediates for the immunogenic conjugates of Group II. The intermediates would be useful for other purposes such as pharmaceuticals. The products of Groups II and III have distinct structures and separate methods for manufacture and use.

JP010115

Microsoft Word – 1st Reading _Abbe_.doc
08/27/07 10:08 AM



First Reading – Abbe

A reading from the Book of Proverbs

My son, do not forget my teaching,
but let your heart keep my commandments,
for length of days and years of life
and peace they will add to you.

Let not steadfast love and faithfulness forsake you;
bind them around your neck;
write them on the tablet of your heart.
So you will find favor and good success
in the sight of God and man.

Trust in the Lord with all your heart,
and do not lean on your own understanding.
In all your ways acknowledge him,
and he will make straight your paths.

The word of the Lord.